Zinc monocysteine

Drug Profile

Zinc monocysteine

Alternative Names: AEN-100; AEN-100/AEN-200; reaZin; Zinc cysteine - Adeona

Latest Information Update: 21 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adeona Pharmaceuticals
  • Developer Synthetic Biologics
  • Class Antidementias; Cysteines; Zinc compounds
  • Mechanism of Action Antioxidants; Free radical scavengers; Glutathione peroxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 16 Feb 2012 Adeona Pharmaceuticals is now called Synthetic Biologics
  • 30 Nov 2011 Efficacy and adverse events data from a phase I/II trial in Amyotrophic lateral sclerosis released by Adeona (ADNM)
  • 30 Sep 2011 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top